Sarepta Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery and development of RNA-based therapeutics for the treatment of serious and life-threatening rare and infectious diseases. Its lead clinical candidate is Eteplirsen, which is in Phase 2 clinical stage for the treatment of Duchenne muscular dystrophy. The company is also developing treatments that are in Phase I clinical trials for infectious diseases, including AVI-7537 for Ebola virus; AVI-7288 for Marburg virus; and AVI-7100 for influenza. Its pre-clinical products comprise Exon 45 PMO and Exon 50 PMO, which are used for the treatment of duchenne muscular dystrophy; and discovery stage products consist of Viral PMO-X for the treatment of dengue fever and Bacterial PPMO used in the treatment of tuberculosis. Sarepta Therapeutics, Inc. has strategic alliances and other material agreements with the U.S. Department of Defense and its agencies, and Karolinska Institutet. The company was formerly known as AVI BioPharma, Inc. and changed its name to Sarepta Therapeutics, Inc. on July 12, 2012. Sarepta Therapeutics, Inc. was founded in 1980 and is headquartered in Bothell, Washington.